CenterBook Partners LP Acquires New Stake in Humacyte, Inc. (NASDAQ:HUMA)

CenterBook Partners LP purchased a new position in Humacyte, Inc. (NASDAQ:HUMA - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 1,279,839 shares of the company's stock, valued at approximately $6,463,000. CenterBook Partners LP owned approximately 1.02% of Humacyte as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HUMA. Vanguard Group Inc. increased its holdings in shares of Humacyte by 10.8% during the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company's stock valued at $28,294,000 after acquiring an additional 543,995 shares in the last quarter. State Street Corp grew its position in Humacyte by 66.1% during the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company's stock valued at $25,917,000 after purchasing an additional 1,895,529 shares during the last quarter. Geode Capital Management LLC increased its stake in Humacyte by 4.7% during the 4th quarter. Geode Capital Management LLC now owns 2,135,133 shares of the company's stock valued at $10,785,000 after purchasing an additional 94,915 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Humacyte by 7.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 775,718 shares of the company's stock worth $3,917,000 after buying an additional 54,400 shares during the last quarter. Finally, Private Advisor Group LLC lifted its stake in shares of Humacyte by 60.7% in the fourth quarter. Private Advisor Group LLC now owns 599,700 shares of the company's stock worth $3,028,000 after buying an additional 226,590 shares in the last quarter. Institutional investors own 44.71% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. D. Boral Capital restated a "buy" rating and issued a $25.00 price objective on shares of Humacyte in a report on Wednesday, March 26th. HC Wainwright restated a "buy" rating and set a $15.00 target price on shares of Humacyte in a research note on Wednesday, March 12th. Finally, Benchmark reiterated a "buy" rating on shares of Humacyte in a research report on Thursday, February 27th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $13.71.

Humacyte Stock Performance

Shares of NASDAQ HUMA traded down $0.07 during midday trading on Monday, reaching $1.47. The stock had a trading volume of 2,297,255 shares, compared to its average volume of 3,559,172. The company has a market capitalization of $212.19 million, a price-to-earnings ratio of -1.09 and a beta of 1.62. Humacyte, Inc. has a 12-month low of $1.15 and a 12-month high of $9.97. The stock has a 50-day moving average of $2.87 and a 200-day moving average of $4.16.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its quarterly earnings results on Friday, March 28th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.07. The business had revenue of $7.23 million for the quarter, compared to the consensus estimate of $0.64 million. As a group, analysts forecast that Humacyte, Inc. will post -1.27 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Dale A. Sander bought 20,000 shares of Humacyte stock in a transaction dated Thursday, April 10th. The shares were purchased at an average cost of $1.53 per share, with a total value of $30,600.00. Following the completion of the acquisition, the chief financial officer now owns 40,600 shares of the company's stock, valued at $62,118. This trade represents a 97.09 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kathleen Sebelius purchased 50,000 shares of the company's stock in a transaction that occurred on Tuesday, April 8th. The shares were purchased at an average cost of $1.32 per share, with a total value of $66,000.00. Following the completion of the purchase, the director now owns 91,207 shares of the company's stock, valued at $120,393.24. The trade was a 121.34 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired 77,500 shares of company stock worth $108,225 in the last three months. 11.20% of the stock is owned by company insiders.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.